<DOC>
	<DOC>NCT00430365</DOC>
	<brief_summary>Maintenance treatment of myeloma.</brief_summary>
	<brief_title>Maintenance Therapy Using Lenalidomide in Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms, Plasma Cell</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>No signs of progression after transplant Effective contraception if necessary (oral contraception for females and barrier methods of contraception for sexually active males) No active severe infection Satisfactory restoration of the haematological parameters defined by: PN &gt;1,000/mm3 and Platelets &gt; 75,000/mm3 Bilirubin &lt; 35 umol/l and GOT/GPT/PAL&lt;3N Creatinine &lt; 160 umol/l.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Myeloma</keyword>
	<keyword>Revlimid</keyword>
	<keyword>Maintenance therapy</keyword>
	<keyword>Autologous Stem Cell Transplantation</keyword>
</DOC>